Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults
抗C5a抗体BDB-001治疗重症COVID-19的安全性、耐受性、药代动力学和药效学:一项在中国健康成年人中进行的随机、双盲、安慰剂对照的1期临床试验
期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-023-00759-4
Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan